[
  {
    "ts": null,
    "headline": "Amgen’s (NASDAQ:AMGN) Q2: Beats On Revenue",
    "summary": "Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.4% year on year to $9.18 billion. The company expects the full year’s revenue to be around $35.5 billion, close to analysts’ estimates. Its non-GAAP profit of $6.02 per share was 14.1% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=87c25bf8c6f2dbccc55bb53e06d206c5c83b4bd071e0cf61108098e676231664",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754436677,
      "headline": "Amgen’s (NASDAQ:AMGN) Q2: Beats On Revenue",
      "id": 136232366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.4% year on year to $9.18 billion. The company expects the full year’s revenue to be around $35.5 billion, close to analysts’ estimates. Its non-GAAP profit of $6.02 per share was 14.1% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=87c25bf8c6f2dbccc55bb53e06d206c5c83b4bd071e0cf61108098e676231664"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Afterhours: AMD, Amgen, Snap",
    "summary": "↘️Advanced Micro Devices (AMD): The stock slipped 3.5% postmarket after the chip maker reported adjusted earnings per share in line with estimates. ↘️Snap (SNAP): Shares of the company behind social-media platform Snapchat slid 14%.",
    "url": "https://finnhub.io/api/news?id=69e49486eb3151a590d367be02019ff8e7718d5802472e43167bd1bbea4edddc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754431223,
      "headline": "Stocks to Watch Afterhours: AMD, Amgen, Snap",
      "id": 136232367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "↘️Advanced Micro Devices (AMD): The stock slipped 3.5% postmarket after the chip maker reported adjusted earnings per share in line with estimates. ↘️Snap (SNAP): Shares of the company behind social-media platform Snapchat slid 14%.",
      "url": "https://finnhub.io/api/news?id=69e49486eb3151a590d367be02019ff8e7718d5802472e43167bd1bbea4edddc"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (AMGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "summary": "While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=dffa077db05dc38c2874423513d1ae95e331ad723ed2a1a74536b643a19405b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754431202,
      "headline": "Amgen (AMGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
      "id": 136232368,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=dffa077db05dc38c2874423513d1ae95e331ad723ed2a1a74536b643a19405b4"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. 2025 Q2 - Results - Earnings Call Presentation",
    "summary": "The following slide deck was published by Amgen Inc.",
    "url": "https://finnhub.io/api/news?id=1d98cad40650672df5315b03ee57246d75bdf952d9b426e46e08fca633517d6c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754430576,
      "headline": "Amgen Inc. 2025 Q2 - Results - Earnings Call Presentation",
      "id": 136230248,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "The following slide deck was published by Amgen Inc.",
      "url": "https://finnhub.io/api/news?id=1d98cad40650672df5315b03ee57246d75bdf952d9b426e46e08fca633517d6c"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. (AMGN) Q2 2025 Earnings Call Transcript",
    "summary": "Amgen Inc. (NASDAQ:AMGN) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ETCompany Participants&amp; - Corporate ParticipantJames E.",
    "url": "https://finnhub.io/api/news?id=b27c8222bec1b3e11e022f80af2e8af1588ba32f0ca63a23d1c64b6350969b97",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754430499,
      "headline": "Amgen Inc. (AMGN) Q2 2025 Earnings Call Transcript",
      "id": 136230249,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen Inc. (NASDAQ:AMGN) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ETCompany Participants&amp; - Corporate ParticipantJames E.",
      "url": "https://finnhub.io/api/news?id=b27c8222bec1b3e11e022f80af2e8af1588ba32f0ca63a23d1c64b6350969b97"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates",
    "summary": "Amgen (AMGN) delivered earnings and revenue surprises of +14.45% and +3.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=608591e064014eec0f469e31d973108e6d88703f51f5afa921e0d0088f736722",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754428502,
      "headline": "Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates",
      "id": 136232369,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) delivered earnings and revenue surprises of +14.45% and +3.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=608591e064014eec0f469e31d973108e6d88703f51f5afa921e0d0088f736722"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Beats Second-Quarter Expectations, So Why Are Shares Diving?",
    "summary": "Amgen crushed second-quarter forecasts late Tuesday. But Amgen stock fell in late-afternoon trading following its report.",
    "url": "https://finnhub.io/api/news?id=c09ed498ec718c44e0b905d673e3c59ce673764e9719fc661d9bbd79a76fa4d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754426999,
      "headline": "Amgen Beats Second-Quarter Expectations, So Why Are Shares Diving?",
      "id": 136232370,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen crushed second-quarter forecasts late Tuesday. But Amgen stock fell in late-afternoon trading following its report.",
      "url": "https://finnhub.io/api/news?id=c09ed498ec718c44e0b905d673e3c59ce673764e9719fc661d9bbd79a76fa4d7"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Posts Higher Profit, Revenue On Sales Growth Among Products",
    "summary": "Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter including Repatha, Evenity and Imdelltra.",
    "url": "https://finnhub.io/api/news?id=4761e1eda5659f1f4516940004b93802aafe738c1ec6c14c3076492e34191713",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754426940,
      "headline": "Amgen Posts Higher Profit, Revenue On Sales Growth Among Products",
      "id": 136232371,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter including Repatha, Evenity and Imdelltra.",
      "url": "https://finnhub.io/api/news?id=4761e1eda5659f1f4516940004b93802aafe738c1ec6c14c3076492e34191713"
    }
  },
  {
    "ts": null,
    "headline": "Amgen inches lower premarket despite second-quarter earnings beat",
    "summary": "Investing.com -- Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit and revenue, with strong product growth across both legacy franchises and newer assets.",
    "url": "https://finnhub.io/api/news?id=584a7b3c81002ee94dc143bef13959c9152ca020342ae9c12ea44dc745b95842",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754426213,
      "headline": "Amgen inches lower premarket despite second-quarter earnings beat",
      "id": 136232372,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Investing.com -- Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit and revenue, with strong product growth across both legacy franchises and newer assets.",
      "url": "https://finnhub.io/api/news?id=584a7b3c81002ee94dc143bef13959c9152ca020342ae9c12ea44dc745b95842"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Q2 Earnings Snapshot",
    "summary": "The results topped Wall Street expectations. The average estimate of 13 analysts surveyed by Zacks Investment Research was for earnings of $5.26 per share. The world's largest biotech drugmaker posted revenue of $9.18 billion in the period, also exceeding Street forecasts.",
    "url": "https://finnhub.io/api/news?id=e7fd22b8298afd4cc8b06416e4cd27900ac7d45fe7bac25c2326eadc54f76992",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754425019,
      "headline": "Amgen: Q2 Earnings Snapshot",
      "id": 136217198,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The results topped Wall Street expectations. The average estimate of 13 analysts surveyed by Zacks Investment Research was for earnings of $5.26 per share. The world's largest biotech drugmaker posted revenue of $9.18 billion in the period, also exceeding Street forecasts.",
      "url": "https://finnhub.io/api/news?id=e7fd22b8298afd4cc8b06416e4cd27900ac7d45fe7bac25c2326eadc54f76992"
    }
  },
  {
    "ts": null,
    "headline": "Amgen quarterly results beat Wall Street estimates",
    "summary": "(Reuters) -Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales offset higher operating expenses.  The California-based biotech company's second-quarter revenue rose 9% from a year earlier to $9.2 billion.  Adjusted earnings per share increased 21% to $6.02.",
    "url": "https://finnhub.io/api/news?id=31aa4adaec5e0d88dcb3d5298630c765599111e26fa28d72cd69bf0b8a640c0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754424171,
      "headline": "Amgen quarterly results beat Wall Street estimates",
      "id": 136217199,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "(Reuters) -Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales offset higher operating expenses.  The California-based biotech company's second-quarter revenue rose 9% from a year earlier to $9.2 billion.  Adjusted earnings per share increased 21% to $6.02.",
      "url": "https://finnhub.io/api/news?id=31aa4adaec5e0d88dcb3d5298630c765599111e26fa28d72cd69bf0b8a640c0e"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS",
    "summary": "Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=23b2c043dbfbee5b356903fa3be62de222a3550838daf532dfb67f7fea85a14c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754424060,
      "headline": "AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS",
      "id": 136217201,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=23b2c043dbfbee5b356903fa3be62de222a3550838daf532dfb67f7fea85a14c"
    }
  },
  {
    "ts": null,
    "headline": "Will Amgen, Already Above Its 50-Day Line, Break Out On This Earnings News?",
    "summary": "Amgen crushed second-quarter forecasts late Tuesday. The news could push Amgen stock, already above its 50-day line, into a breakout.",
    "url": "https://finnhub.io/api/news?id=332393613c4fadf6024fa2d12fe49b3fbd9332f568e8e22df454800b6b557cc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754424033,
      "headline": "Will Amgen, Already Above Its 50-Day Line, Break Out On This Earnings News?",
      "id": 136217202,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen crushed second-quarter forecasts late Tuesday. The news could push Amgen stock, already above its 50-day line, into a breakout.",
      "url": "https://finnhub.io/api/news?id=332393613c4fadf6024fa2d12fe49b3fbd9332f568e8e22df454800b6b557cc9"
    }
  },
  {
    "ts": null,
    "headline": "Macro Data, Trade Developments Leave Equities Mixed Intraday",
    "summary": "US benchmark equity indexes were mixed intraday as markets tracked the latest economic data and trad",
    "url": "https://finnhub.io/api/news?id=aaf063087a81280df543536b76fdeee831f322e962c6c4d58d446fd20e679cca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754418975,
      "headline": "Macro Data, Trade Developments Leave Equities Mixed Intraday",
      "id": 136217138,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "US benchmark equity indexes were mixed intraday as markets tracked the latest economic data and trad",
      "url": "https://finnhub.io/api/news?id=aaf063087a81280df543536b76fdeee831f322e962c6c4d58d446fd20e679cca"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Beats Second-Quarter Expectations, So Why Are Sharing Diving?",
    "summary": "Amgen Beats Second-Quarter Expectations, So Why Are Sharing Diving?",
    "url": "https://finnhub.io/api/news?id=efcca5f6501b3234004a11d20caa082c617d1cbd58bbcc69f52e69a59eefbf4a",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754412599,
      "headline": "Amgen Beats Second-Quarter Expectations, So Why Are Sharing Diving?",
      "id": 136236097,
      "image": "",
      "related": "AMGN",
      "source": "DowJones",
      "summary": "Amgen Beats Second-Quarter Expectations, So Why Are Sharing Diving?",
      "url": "https://finnhub.io/api/news?id=efcca5f6501b3234004a11d20caa082c617d1cbd58bbcc69f52e69a59eefbf4a"
    }
  },
  {
    "ts": null,
    "headline": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "url": "https://finnhub.io/api/news?id=764c851f16c5a4a1b78beb2933fcdbd99b7c94d5c61448ad8c3dd9ad5fc1d1f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754399401,
      "headline": "3 Top Dividend Stocks to Maximize Your Retirement Income",
      "id": 136215004,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
      "url": "https://finnhub.io/api/news?id=764c851f16c5a4a1b78beb2933fcdbd99b7c94d5c61448ad8c3dd9ad5fc1d1f6"
    }
  },
  {
    "ts": null,
    "headline": "Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic’s Scientific Advisory Board",
    "summary": "SAN DIEGO, August 05, 2025--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced that Ray Deshaies, PhD, has joined its scientific advisory board. A biochemist and cell biologist, Dr. Deshaies most recently led global research for Amgen following a distinguished academic career at the California Institute of Technology.",
    "url": "https://finnhub.io/api/news?id=8610e65078a5d3475296eec19a7cc24ef6a529e39f054af8095800149136cb14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754395200,
      "headline": "Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic’s Scientific Advisory Board",
      "id": 136212395,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "SAN DIEGO, August 05, 2025--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced that Ray Deshaies, PhD, has joined its scientific advisory board. A biochemist and cell biologist, Dr. Deshaies most recently led global research for Amgen following a distinguished academic career at the California Institute of Technology.",
      "url": "https://finnhub.io/api/news?id=8610e65078a5d3475296eec19a7cc24ef6a529e39f054af8095800149136cb14"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Rise Pre-Bell Ahead of Latest Corporate Earnings; Investors Monitor Tariff Developments",
    "summary": "US equity futures were pointing higher on Tuesday as investors await the latest batch of corporate e",
    "url": "https://finnhub.io/api/news?id=4c8370090f604a6c434076e1b5d15673ec44b8e343be987d6e305b88b4b5d94b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754393676,
      "headline": "Stocks Rise Pre-Bell Ahead of Latest Corporate Earnings; Investors Monitor Tariff Developments",
      "id": 136212267,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "US equity futures were pointing higher on Tuesday as investors await the latest batch of corporate e",
      "url": "https://finnhub.io/api/news?id=4c8370090f604a6c434076e1b5d15673ec44b8e343be987d6e305b88b4b5d94b"
    }
  },
  {
    "ts": null,
    "headline": "Global Markets Rise on Fed Rate-Cut Hopes",
    "summary": "U.S. stock futures rose, the dollar was steady and two- and 10-year Treasury yields edged higher as Trump moves to make some key hires at the Fed and Bureau of Labor Statistics.",
    "url": "https://finnhub.io/api/news?id=be3b2804c18129dfae810ab89b4c2e70028c815f44b47db90e0c61fff8f6d659",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754382720,
      "headline": "Global Markets Rise on Fed Rate-Cut Hopes",
      "id": 136212295,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "U.S. stock futures rose, the dollar was steady and two- and 10-year Treasury yields edged higher as Trump moves to make some key hires at the Fed and Bureau of Labor Statistics.",
      "url": "https://finnhub.io/api/news?id=be3b2804c18129dfae810ab89b4c2e70028c815f44b47db90e0c61fff8f6d659"
    }
  },
  {
    "ts": null,
    "headline": "Cystinosis Global Market Research Report 2025-2035 | Orphan Drug Incentives, Innovative Cysteamine Delivery, Gene Therapy Potential, and Early Diagnosis Fueling Advancements",
    "summary": "The cystinosis market is poised for growth amid increasing newborn screening, innovative cysteamine formulations, and potential gene therapy breakthroughs. As a rare metabolic disorder, cystinosis is marked by cystine accumulation, primarily affecting kidneys and eyes. While cysteamine remains a cornerstone treatment, its long-term use presents challenges. Advances in gene therapy trials, renal transplantation, and metabolic screening are enhancing patient management. North America leads the mar",
    "url": "https://finnhub.io/api/news?id=6fe6525205f09bb0fee920e47355e49ff4e113e16f11770662d15148c7d02783",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754381100,
      "headline": "Cystinosis Global Market Research Report 2025-2035 | Orphan Drug Incentives, Innovative Cysteamine Delivery, Gene Therapy Potential, and Early Diagnosis Fueling Advancements",
      "id": 136212398,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The cystinosis market is poised for growth amid increasing newborn screening, innovative cysteamine formulations, and potential gene therapy breakthroughs. As a rare metabolic disorder, cystinosis is marked by cystine accumulation, primarily affecting kidneys and eyes. While cysteamine remains a cornerstone treatment, its long-term use presents challenges. Advances in gene therapy trials, renal transplantation, and metabolic screening are enhancing patient management. North America leads the mar",
      "url": "https://finnhub.io/api/news?id=6fe6525205f09bb0fee920e47355e49ff4e113e16f11770662d15148c7d02783"
    }
  },
  {
    "ts": null,
    "headline": "Calcinosis Cutis Market Research Report 2025-2035 | Market Shifts Toward Targeted Therapies as Advances in Calcium Metabolism Research Drive Development of More Effective Treatments",
    "summary": "Calcinosis Cutis is a rare disorder marked by calcium deposits in the skin, often linked to autoimmune diseases like dermatomyositis, systemic sclerosis, and lupus, as well as chronic kidney disease. Symptoms include painful, nodular formations that can lead to complications such as ulcers or restricted movement. Treatment focuses on addressing underlying conditions using phosphate binders, bisphosphonates, or surgery. The market is expanding due to rising autoimmune cases and advances in treatm",
    "url": "https://finnhub.io/api/news?id=183c24eb08924f06497d4f8656ca6124cb17b13a491d5b4452e3b9b4fa10168d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754380860,
      "headline": "Calcinosis Cutis Market Research Report 2025-2035 | Market Shifts Toward Targeted Therapies as Advances in Calcium Metabolism Research Drive Development of More Effective Treatments",
      "id": 136212400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Calcinosis Cutis is a rare disorder marked by calcium deposits in the skin, often linked to autoimmune diseases like dermatomyositis, systemic sclerosis, and lupus, as well as chronic kidney disease. Symptoms include painful, nodular formations that can lead to complications such as ulcers or restricted movement. Treatment focuses on addressing underlying conditions using phosphate binders, bisphosphonates, or surgery. The market is expanding due to rising autoimmune cases and advances in treatm",
      "url": "https://finnhub.io/api/news?id=183c24eb08924f06497d4f8656ca6124cb17b13a491d5b4452e3b9b4fa10168d"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary",
    "summary": "Janus Henderson Global Life Sciences Diversified ADR Managed Account returned -3.68% (gross) and the MSCI World Health Care Index returned -3.96%. Read more here.",
    "url": "https://finnhub.io/api/news?id=43278605299a51388bd3eed265ac982c872aaf1763e0851ee415ae42adb8f45e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754374920,
      "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary",
      "id": 136207822,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/171573445/image_171573445.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Janus Henderson Global Life Sciences Diversified ADR Managed Account returned -3.68% (gross) and the MSCI World Health Care Index returned -3.96%. Read more here.",
      "url": "https://finnhub.io/api/news?id=43278605299a51388bd3eed265ac982c872aaf1763e0851ee415ae42adb8f45e"
    }
  }
]